STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Fourth Addendum sets TCNT patent payments at $50,000/month

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Ainos, Inc. entered a Fourth Addendum to its Product Development Agreement with Taiwan Carbon Nano Technology Corporation (TCNT). The amendment sets a fee for the exclusive use of patents of $50,000 per month plus 5% sales tax for a two-year period starting October 16, 2025, replacing the prior one-year period starting October 16, 2024.

TCNT controls the company through its majority interest in Ainos KY and direct ownership, with Ainos KY holding majority voting power via voting agreements. The parties may negotiate payment terms and subsequent licensing methods after the two-year period. An English translation of the Fourth Addendum is filed as Exhibit 10.1.

Positive

  • None.

Negative

  • None.

Insights

Two-year, related-party patent fee set at $50,000/month.

The company amended its agreement with TCNT to pay $50,000 per month plus 5% sales tax for the exclusive use of patents. The term runs for two years beginning October 16, 2025, replacing a previously referenced one-year period starting October 16, 2024.

This is a related-party arrangement: TCNT controls the company via stakes in Ainos KY and direct ownership, with voting agreements conferring majority voting power. That context underscores governance considerations around pricing and approvals.

After the two-year period, the parties may negotiate payment terms and subsequent licensing methods. Details of the amendment are provided in Exhibit 10.1, offering disclosure of the operative terms.

false 0001014763 0001014763 2025-10-15 2025-10-15 0001014763 AIMD:CommonStockParValue0.01PerShareMember 2025-10-15 2025-10-15 0001014763 AIMD:WarrantsToPurchaseCommonStockMember 2025-10-15 2025-10-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 15, 2025

 

AINOS, INC.
(Exact name of registrant as specified in its charter)

 

Texas   001-41461   75-1974352

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

8880 Rio San Diego Drive, Ste. 800, San Diego, CA 92108

(858) 869-2986

(Address and telephone number, including area code, of registrant’s principal executive offices)

 

 

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   AIMD   The Nasdaq Stock Market LLC
Warrants to purchase Common Stock   AIMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

As previously reported, on August 1, 2021, Ainos, Inc. ( the “Company”) entered into a five-year product development agreement (the “Product Development Agreement”) with Taiwan Carbon Nano Technology Corporation (“TCNT”), as amended on January 9, 2024, July 8, 2024, and October 16, 2024, to co-develop pharmaceutical, medical device and other products defined in the agreement. TCNT controls the company via its majority interest in Ainos Inc., a Cayman Islands corporation (“Ainos KY”) and its direct ownership in the Company. Ainos KY is a shareholder of the Company and holds majority control of the voting power of the Company through certain previously disclosed voting agreements.

 

On October 15, 2025, the Company and TCNT entered into the fourth addendum to the Product Development Agreement (the “Fourth Addendum Agreement”) to amend the fee for the exclusive use of patents of $50,000 per month (plus 5% sales tax) for a two-year period starting from October 16, 2025, instead of one year starting from October 16, 2024. The parties may negotiate payment terms and subsequent licensing methods thereafter.

 

The foregoing description of the Fourth Addendum Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Addendum Agreement, an English translation of which is filed with this current report on Form 8-K as Exhibit 10.1 and is hereby incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Exhibits
10.1   English Translation of Fourth Addendum to Product Development Agreement, dated October 15, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ainos, Inc.
     
Date: October 17, 2025 By: /s/ Chun-Hsien Tsai
  Name: Chun-Hsien Tsai
  Title: Chief Executive Officer

 

 

 

FAQ

What did Ainos (AIMD) announce in this 8-K?

Ainos entered a Fourth Addendum with TCNT, setting a patent-use fee of $50,000 per month plus 5% sales tax for a two-year period starting October 16, 2025.

How long is the amended patent-use fee in effect for AIMD?

The fee applies for a two-year period beginning October 16, 2025.

What fee did AIMD agree to pay under the addendum?

A monthly fee of $50,000 plus 5% sales tax for the exclusive use of patents.

Who is TCNT and what is its relationship to Ainos (AIMD)?

TCNT controls the company via its majority interest in Ainos KY and direct ownership, with Ainos KY holding majority voting power through voting agreements.

When does the amended fee start for Ainos (AIMD)?

The two-year period starts on October 16, 2025.

Is the full agreement available?

Yes. An English translation of the Fourth Addendum is filed as Exhibit 10.1.
Ainos Inc

NASDAQ:AIMD

AIMD Rankings

AIMD Latest News

AIMD Latest SEC Filings

AIMD Stock Data

12.03M
1.66M
56.73%
0.13%
2.59%
Medical Devices
Pharmaceutical Preparations
Link
United States
SAN DIEGO